• Product NameTemsirolimus (CCI-779, NSC 683864)
• Brief DescriptionInhibitors
• Purification99.50%
• Biological ActivityTemsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel.
• Target NamemTOR inhibitor
• CAS No. 162635-04-3
• Calculated MW 1030.29
• Formulation C56H87NO16
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Immunology
  SMILES:C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC
  Pathways:PI3K/Akt/mTOR signaling
  Receptor:mTOR
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 75 mg/mL (72.79 mM); DMSO: 75 mg/mL (72.79 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Shor B, et al. Y Res, 2008, 68(8), 2934-2943.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting